

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action within 48 Hours

Pharmacy and Wholesaler Level Recall

Dear Healthcare Professional

Bristol Laboratories Limited

PL 17907/0421

**Irbesartan 75 mg Film Coated
Tablets**

Batch Number	Expiry Date	Pack Size	First Distributed
POM0007	February 2023	28	8 Dec 2020
POM0008	February 2023	28	13 Jan 2021
POM0009	February 2023	28	18 Feb 2021
POM0010	February 2023	28	20 Apr 2021

**Irbesartan 150 mg Film Coated
Tablets**

PL 17907/0422

Batch Number	Expiry Date	Pack Size	First Distributed
PON0005	January 2023	28	15 Feb 2021
PON0006	January 2023	28	8 Mar 2021
PON0007	January 2023	28	29 Mar 2021
PON0008	January 2023	28	12 Apr 2021
PON0009	January 2023	28	20 Apr 2021

**Irbesartan 300 mg Film Coated
Tablets**

PL 17907/0423

Batch Number	Expiry Date	Pack Size	First Distributed
POO0005	February 2023	28	30 Nov 2020

Active Pharmaceutical Ingredient: irbesartan

Brown and Burk UK Ltd **PL 25298/0073**
Irbesartan 75mg Film Coated
Tablets

Batch Number	Expiry Date	Pack Size	First Distributed
IAAG017	May 2022	28	15 Nov 2019
IAAG018	May 2022	28	14 Oct 2019
IAAG019	May 2022	28	13 Feb 2020
IAAG022	Aug 2022	28	19 Mar 2020
IAAG023	Aug 2022	28	17 Nov 2020

Irbesartan 150mg Film Coated **PL 25298/0074**
Tablets

Batch Number	Expiry Date	Pack Size	First Distributed
IABG033	May 2022	28	09 Sep 2019
IABG034	May 2022	28	16 Sep 2019
IABG035	May 2022	28	22 Oct 2019
IABG037	July 2022	28	05 Dec 2019
IABG038	July 2022	28	17 Feb 2020
IABG039	July 2022	28	13 Feb 2020
IABG051	Jan 2023	28	27 May 2020

Irbesartan 300mg Film Coated **PL 25298/0075**
Tablets

Batch Number	Expiry Date	Pack Size	First Distributed
IACG027	Jun 2022	28	22 Nov 2019
IACG028	Jun 2022	28	17 Dec 2019
IACG032	Jun 2022	28	27 Feb 2020
IACG035	Sep 2022	28	09 Mar 2020
IACG036	Sep 2022	28	15 Apr 2020
IACG037	Sep 2022	28	19 May 2020

Irbesartan/Hydrochlorothiazide **PL 25298/0070**
150mg/12.5mg Film Coated
Tablets

Batch Number	Expiry Date	Pack Size	First Distributed
IZAG020	May 2023	28	10 Nov 2020



Active Pharmaceutical Ingredient: irbesartan

**Irbesartan/Hydrochlorothiazide
300mg/12.5mg Film Coated
Tablets** PL 25298/0071

Batch Number	Expiry Date	Pack Size	First Distributed
IZCG010	Aug 2022	28	23 Dec 2019

**Irbesartan/Hydrochlorothiazide
300mg/25mg Film Coated
Tablets** PL 25298/0072

Batch Number	Expiry Date	Pack Size	First Distributed
IZBG008	Jul 2022	28	14 May 2020

Teva UK Ltd

Losartan Potassium 50mg Film Coated Tablets PL 00289/0964

Batch Number	Expiry Date	Pack Size	First Distributed
108885	May 2023	28	04 Nov 2020

Losartan Potassium 100mg Film Coated Tablets PL 00289/0965

Batch Number	Expiry Date	Pack Size	First Distributed
106077	October 2022	28	18 Mar 2020

Active Pharmaceutical Ingredient: losartan potassium

Brief description of the problem

Bristol Laboratories Limited, Brown & Burk UK Ltd and Teva UK Ltd are recalling the above batches of products as a precautionary measure due to contamination with an impurity called 5-(4'-(azidomethyl)-[1,1'-biphenyl]-2yl)-1H-tetrazole, which has mutagenic potential. These batches are being recalled as the level of contamination is above the acceptable limit. Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

Advice for healthcare professionals

Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.



Patients are advised not to stop taking their medication prior to consultation with their doctor or pharmacist, as the health risk of discontinuing the medicine is higher than the potential risk presented by the impurity. This recall is being undertaken as a precautionary measure to prevent further exposure to this impurity in the affected medicines whilst the investigation is ongoing.

There are no anticipated shortages of irbesartan-containing and losartan-containing products in the UK as a result of this recall. However, this is a developing issue and MHRA is working with Marketing Authorisation Holders and other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

Further Information

Bristol Laboratories Limited

For more information or medical information queries please contact notifications@bristol-labs.co.uk

For supply queries, please contact notifications@bristol-labs.co.uk

Brown & Burk UK Ltd

For more information or medical information queries please contact pv@bbukltd.com

For supply queries, please contact customercare@bbukltd.com or 0203 384 7188

Teva UK Limited

For more information or medical information queries please contact Teva Medical Information at medinfo@tevauk.com or 0207 540 7117

For supply queries, please contact Teva Customer Solutions at customer.services@tevauk.com or 0800 590502

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this notice.

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

TO ALL CHEMISTS, DOCTORS ON THE LISTS

Pharmaceutical Services
2 Franklin Street
BELFAST
BT2 8DQ

Telephone No. 028 9536 0333

17th June 2021

Pharmaceutical website: <http://www.hscbusiness.hscni.net>